Physician

Patrick Vincent Acevedo, M.D.

According to 2025 Medicare claims, Patrick Acevedo, M.D. (NPI: 1639132269) practices medical oncology in the Ocala, FL market, with the plurality of this provider's patient population coming from Marion, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32159-8984.

Acevedo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,281 traditional Medicare patients, billed 340,437 HCPCS/CPT codes, and received $4,790,894 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,153 prescription claims across 467 beneficiaries totaling $7,375,784 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 59 claims. Open Payments data shows 116 records totaling $2,517. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $14,406 to $693.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,420	414,406	$4,981,880
2016	4,494	542,568	$7,179,428
2017	2,134	576,280	$5,493,048
2018	2,150	604,953	$6,538,270
2019	1,998	412,416	$5,453,931
2020	1,800	373,274	$5,023,030
2021	1,596	413,525	$5,125,784
2022	1,496	413,179	$4,926,582
2023	1,311	339,719	$4,633,704
2024	1,281	340,437	$4,790,894

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	613	4,181	$4,392,046
2016	570	3,973	$4,969,538
2017	558	3,557	$4,882,204
2018	564	3,508	$6,532,941
2019	469	2,526	$5,966,254
2020	413	2,282	$5,138,880
2021	386	1,988	$4,842,002
2022	391	1,924	$5,313,308
2023	407	1,910	$4,497,747
2024	467	2,153	$7,375,784

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	196	$32,674
2016	25	469	$135,469
2017	21	314	$80,691
2018	15	82	$7,619
2019	14	103	$10,131
2020	N/R	197	$90,872
2021	N/R	139	$10,678
2022	N/R	116	$6,935
2023	N/R	59	$6,209
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	752	1,845	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	454	779	$13
96372	Injection of drug or substance under skin or into muscle	243	1,050	$10
36415	Insertion of needle into vein for collection of blood sample	951	3,069	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	920	3,052	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	100	2,751	$1,747,984
Brukinsa	Zanubrutinib	68	2,024	$852,462
Xtandi	Enzalutamide	58	1,740	$747,729
Imbruvica	Ibrutinib	33	950	$412,518
Idhifa	Enasidenib Mesylate	12	360	$409,983

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	116	$2,517	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Patrick Vincent Acevedo, M.D.?

Tedicare shows public-source Medicare data for Patrick Vincent Acevedo, M.D. (NPI 1639132269), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Patrick Vincent Acevedo, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Patrick Vincent Acevedo, M.D.?

Patrick Vincent Acevedo, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Patrick Vincent Acevedo, M.D. have Open Payments data?

Patrick Vincent Acevedo, M.D. has 116 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.